NCT01715012终止2 期
A Phase 2a Randomized, Double Blind, Placebo Controlled, Single-center Study of ST266 Spray in Diabetic Subjects With Deep Burns Managed With Meshed Skin Grafts.
Noveome Biotherapeutics, formerly Stemnion1 个研究点 分布在 1 个国家目标入组 1 人开始时间: 2012年10月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 发起方
- 入组人数
- 1
- 试验地点
- 1
- 主要终点
- Safety
研究概览
简要总结
This study is a randomized, double blind, placebo controlled trial at a single site. The primary objective is to evaluate the safety of ST266 in diabetic subjects with deep burns. The secondary objectives of this study are to (1) evaluate efficacy of ST266 in healing burns and (2) evaluate whether treatment with ST266 results in less scarring, in subjects with diabetes separately comparing healing of the skin graft and the skin graft donor site using ST266 plus a burn dressing versus placebo and a burn dressing.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed and dated Institutional Review Board-approved written Informed Consent
- •18 - 75 years of age.
- •Thermal or scald burn, either full thickness or deep partial thickness, which in the opinion of the burn surgeon, requires a meshed skin graft to heal.
- •Target burn area for treatment equal to or less than three percent total body surface area.
- •A skin graft site harvested at 10/1000ths of an inch and a skin graft meshed at 2:
- •Total Body Surface Area (TBSA) burn of less than or equal to 20 percent total body surface.
- •Patient must have a known history of diabetes, or be found to have diabetes at the time of admission, confirmed by a Hemoglobin A1C of greater than 6.5 percent.
- •If a woman of child-bearing potential (WOCBP), she and her partner must be willing to employ either a highly effective form of birth control (e.g., implants, injectable medications, a hormone combination oral contraceptive, etc.), sexual abstinence, or a vasectomised partner, in combination with a barrier method, for the entire duration of the study (through study discharge). Male subjects with a WOCBP partner must be willing to use a condom during sexual activity for the entire duration of the study (through study discharge).
- •Willing to participate in the clinical study and comply with the requirements of the trial.
排除标准
- •Full thickness burns involving tendon, ligament, bone, or joint capsule.
- •Burns of the face, neck, palmer surface of the hands and plantar surface of the foot.
- •Burn from chemical, electrical or radiation causes.
- •Subjects with any immune deficiency including current treatment with corticosteroid medication, chemotherapeutic agents, anti-viral therapy, or concurrent radiation therapy within 30 days of signing the informed consent.
- •Active cancer or a history of cancer in the five years prior to signing the informed consent form. (History of basal cell carcinoma is allowed).
- •Life expectancy of less than one year.
- •Patients requiring care in the Intensive Care Unit.
- •Inhalation injury requiring mechanical ventilation.
- •Multiple trauma (significant traumatic injury to a solid organ in addition to skin).
- •Psychiatric condition or substance abuse which in the Investigator's opinion may pose a threat to subject compliance.
- •History of non-compliance with treatment or clinical visit attendance.
- •Participation in an investigational trial within 30 days of study entry.
- •Women who are pregnant or lactating
- •Prisoners
- •Acute clinically significant infection (including viral infections) in the six weeks prior to administration of study drug or any clinically significant ongoing chronic infection (excluding fungal infections of the nail beds).
- •Evidence or history of skin conditions that would interfere with evaluations.
- •Any other uncontrolled concomitant disease, condition, or treatment that could interfere with the conduct of the study, or that would, in the opinion of the investigator, pose an unacceptable risk to individuals in this study or interfere with the interpretation of study data.
研究组 & 干预措施
ST266
Experimental
ST266 sprayed to the skin graft and donor site
干预措施: ST266 (Biological)
Saline
Placebo Comparator
Saline (placebo)sprayed to the skin graft and donor site
干预措施: Saline (Drug)
结局指标
主要结局
Safety
时间窗: Beginning at enrollment and continuing 12 months after last treatment
The primary objective of this study is to evaluate the safety of ST266 in treating burns in diabetic subjects by evaluating adverse events and serious adverse events. Physical examination, hematology, serum chemistry, urinalysis, vital signs, Adverse Event monitoring, and concomitant medications, cytokine and antibody levels will be monitored at baseline and during the study.
次要结局
- Healing of skin graft(Up to 2 weeks of treatment)
- Healing of skin graft donor site(Up to 2 weeks of treatment)
- Scarring of skin graft(One year following treatment)
- Scarring of skin graft donor site(One year following treatment)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Safety and Efficacy of SM934 Compared to Placebo in Adult Subjects With Active Systemic Lupus ErythematosusSystemic Lupus ErythematosusNCT03951259RenJi Hospital32
进行中（未招募）
2 期
Dose-finding Study of SAR443122 in Adult Participants With Ulcerative ColitisColitis UlcerativeNCT05588843Sanofi187
已完成
2 期
A Healthy Volunteer Pharmacokinetics (PK)/Pharmacodynamics (PD), Safety and Tolerability Study of Andexanet in Healthy Japanese and Caucasian SubjectsBleedingNCT03310021Portola Pharmaceuticals108
已完成
2 期
MCC-135 as Adjunct Therapy to Primary Percutaneous Coronary Intervention in ST-Segment Elevation Acute Myocardial Infarction PatientsMyocardial InfarctionNCT00078013Tanabe Pharma Corporation414
撤回
2 期
Study Evaluating the Efficacy of Hydroxychloroquine and Azithromycine in Patients With COVID-19 and Hematological Malignancies (HYACINTHE)COVID19Hematologic MalignancyNCT04392128Institut de cancérologie Strasbourg Europe